Fulgent Genetics, Inc.

NasdaqGM:FLGT Stok Raporu

Piyasa değeri: US$547.2m

Fulgent Genetics Yönetim

Yönetim kriter kontrolleri 2/4

Fulgent Genetics CEO'su Ming Hsieh, May2016 tarihinde atandı, in görev süresi 8.5 yıldır. in toplam yıllık tazminatı $ 5.31M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.8% maaş ve 81.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 28.52% ine doğrudan sahiptir ve bu hisseler $ 156.09M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.7 yıl ve 3.8 yıldır.

Anahtar bilgiler

Ming Hsieh

İcra Kurulu Başkanı

US$5.3m

Toplam tazminat

CEO maaş yüzdesi18.8%
CEO görev süresi8.5yrs
CEO sahipliği28.5%
Yönetim ortalama görev süresi4.7yrs
Yönetim Kurulu ortalama görev süresi3.8yrs

Son yönetim güncellemeleri

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Recent updates

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Sep 09

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Jul 17
Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

CEO Tazminat Analizi

Ming Hsieh'un ücretlendirmesi Fulgent Genetics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$165m

Jun 30 2024n/an/a

-US$163m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$5mUS$1m

-US$168m

Sep 30 2023n/an/a

-US$64m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$5mUS$948k

US$143m

Sep 30 2022n/an/a

US$272m

Jun 30 2022n/an/a

US$392m

Mar 31 2022n/an/a

US$461m

Dec 31 2021US$6mUS$664k

US$507m

Sep 30 2021n/an/a

US$569m

Jun 30 2021n/an/a

US$493m

Mar 31 2021n/an/a

US$417m

Dec 31 2020US$248kUS$240k

US$214m

Sep 30 2020n/an/a

US$48m

Jun 30 2020n/an/a

US$3m

Mar 31 2020n/an/a

-US$459k

Dec 31 2019US$240kUS$240k

-US$411k

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$240kUS$240k

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$5m

Dec 31 2017US$240kUS$240k

-US$3m

Tazminat ve Piyasa: Ming 'nin toplam tazminatı ($USD 5.31M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.11M ).

Tazminat ve Kazançlar: Ming şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Ming Hsieh (68 yo)

8.5yrs

Görev süresi

US$5,309,167

Tazminat

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Ming Hsieh
Chairman & CEO8.5yrsUS$5.31m28.52%
$ 156.1m
Jian Xie
COO & President6.6yrsUS$1.79m1.42%
$ 7.8m
Paul Kim
Chief Financial Officer8.8yrsUS$1.78m0.40%
$ 2.2m
Hanlin Gao
Chief Scientific Officer & Laboratory Director8.2yrsUS$1.49m2.8%
$ 15.3m
Natalie Prescott
General Counsel & Chief Privacy Officer2.5yrsVeri yokVeri yok
Doreen Ng
VP of Operations & Compliance and GM of Houston Office4.1yrsVeri yokVeri yok
Jakub Sram
Vice President of Business Development & Sales9.8yrsVeri yokVeri yok
Ellen Tsui
Vice President of Human Resources2.5yrsVeri yokVeri yok
Brandon Perthuis
Chief Commercial Officer4.7yrsVeri yokVeri yok
Lawrence Weiss
Chief Medical Officer3.5yrsVeri yokVeri yok
Ray Yin
President & Chief Scientific Officer of Fulgent Pharma2yrsVeri yokVeri yok

4.7yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: FLGT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.7 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ming Hsieh
Chairman & CEO8.5yrsUS$5.31m28.52%
$ 156.1m
Regina Groves
Independent Non-Employee Director1.8yrsUS$625.60k0.0039%
$ 21.2k
Linda Marsh
Independent Director5.3yrsUS$270.50k0.061%
$ 333.8k
Michael Nohaile
Independent Non-Employee Director2.3yrsUS$268.50k0.0078%
$ 42.6k

3.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FLGT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).